The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Two-Week Treatment Period

This study has been completed.
Information provided by:
Merck Sharp & Dohme Corp. Identifier:
First received: May 1, 2009
Last updated: September 20, 2011
Last verified: September 2011

The objective of this study is to compare the safety and efficacy of azithromycin ophthalmic solution, 1% versus placebo over a two-week treatment period.

Condition Intervention Phase
Drug: Azithromycin ophthalmic solution, 1%
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • Eyelid margin erythema [ Time Frame: Two weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Signs and symptoms of Blepharitis [ Time Frame: One week, two weeks, three weeks, four weeks ] [ Designated as safety issue: No ]

Enrollment: 313
Study Start Date: April 2009
Study Completion Date: January 2010
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: Azithromycin ophthalmic solution, 1%
One drop in each eye twice a day for the first two days; then one drop in each eye once a day for 12 days
Placebo Comparator: 2 Drug: Placebo
One drop in each eye twice a day for the first two days; then one drop in each eye once a day for 12 days


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Have best corrected visual acuity in both eyes of at least +0.7 or better
  • If female, are non-pregnant or non-lactating
  • Have a current diagnosis of blepharitis in one or both eyes

Exclusion Criteria:

  • Have lid structural abnormalities
  • Have suspected ocular fungal or viral infection
  • Have practiced warm compress therapy within 14 days prior to Visit 2
  • Unable to withhold the use of contact lenses during the treatment or follow-up periods
  • Unable to withhold the use of ocular cosmetic products within 24 hours prior to study visits
  • Have had penetrating intraocular surgery within 90 days prior to Visit 2
  • Have had ocular surface surgery within the past year prior to Visit 2
  • Have a serious medical condition which could confound study assessments
  Contacts and Locations
Please refer to this study by its identifier: NCT00892970

  Show 33 Study Locations
Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Study Chair: Reza Haque, MD, PhD Medical Monitor, Inspire
  More Information

No publications provided

Responsible Party: Mike Schiewe, Inspire Identifier: NCT00892970     History of Changes
Other Study ID Numbers: 044-101, P08639
Study First Received: May 1, 2009
Last Updated: September 20, 2011
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Eyelid Diseases
Eye Diseases
Anti-Bacterial Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions processed this record on April 17, 2014